Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Total Debt (2021 - 2026)

ADC Therapeutics has reported Total Debt over the past 6 years, most recently at $115.7 million for Q1 2026.

  • Quarterly results put Total Debt at $115.7 million for Q1 2026, up 1.65% from a year ago — trailing twelve months through Mar 2026 was $115.7 million (up 1.65% YoY), and the annual figure for FY2025 was $115.5 million, up 1.6%.
  • Total Debt reached $115.7 million in Q1 2026 per ADCT's latest filing, roughly flat from $115.5 million in the prior quarter.
  • Across five years, Total Debt topped out at $115.7 million in Q1 2026 and bottomed at $112.7 million in Q4 2023.
  • Median Total Debt over the past 5 years was $114.2 million (2024), compared with a mean of $114.3 million.
  • The largest annual shift saw Total Debt soared 32.15% in 2022 before it fell 2.15% in 2023.
  • Over 5 years, Total Debt stood at $115.2 million in 2022, then dropped by 2.15% to $112.7 million in 2023, then grew by 0.83% to $113.6 million in 2024, then rose by 1.6% to $115.5 million in 2025, then increased by 0.19% to $115.7 million in 2026.
  • Business Quant data shows Total Debt for ADCT at $115.7 million in Q1 2026, $115.5 million in Q4 2025, and $115.2 million in Q3 2025.